SC 13G/A: Corbus Pharmaceuticals Holdings, Inc.

AI Summary

SC 13G/A filing by Corbus Pharmaceuticals Holdings, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value, $0.0001 per share (Title of Class of Securiti
• $208.80 — of Common Stock at an exercise price of $208.80 per share (as adjusted by the 1-for-30

Filing Documents

• ef20038297_sc13ga.htm (SC 13G/A) — 113KB
• 0001140361-24-046892.txt ( ) — 115KB

(a)

Item 1(a). Name of Issuer: Corbus Pharmaceuticals Holdings, Inc. (the "Issuer")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 500 River Ridge Drive, Norwood, MA 02062

(a)

Item 2(a). Name of Person Filing: This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. K2 HealthVentures Equity Trust LLC ("K2HV Equity"); ii. Parag Shah ("Mr. Shah"); and iii. Anup Arora ("Mr. Arora"). This Statement on Schedule 13G relates to shares of Common Stock (as defined herein) that the Reporting Persons have the right to acquire within 60 days upon exercise of warrants to purchase 2,873 shares of Common Stock at an exercise price of $208.80 per share (as adjusted by the 1-for-30 reverse stock split the Issuer completed on February 14, 2023, which warrants expire on July 28, 2030 (the "Warrants")), directly held by K2HV Equity. K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon exercise of the Warrants, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.

(c)

Item 2(c). Citizenship: K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.

(d)

Item 2(d). Titles of Classes of Securities: Common Stock, par value $0.0001 per share ("Common Stock")

(e)

Item 2(e). CUSIP Number: 21833P301 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: This Item 3 is not applicable. CUSIP No. 21833P301 Page 6 of 9 Pages Item 4.

(a)

Item 4(a). Amount Beneficially Owned: As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of 2,873 shares of Common Stock that K2HV Equity has the right to acquire within 60 days upon exercise of the Warrants.

(b)

Item 4(b). Percent of Class: As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 0.02% of the shares of Common Stock outstanding. The percentages set forth herein are calculated based on the sum of: (i) 12,043,940 shares of Common Stock outstanding as of August 2, 2024, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2024, and (ii) 2,873 shares of Common Stock that are issuable to the Reporting Persons within 60 days upon exercise of the Warrants, which shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

(c)

Item 4(c). Number of Shares as to which such person has: K2HV Equity, Mr. Shah and Mr. Arora (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 2,873 (iii) Sole power to dispose or direct the disposition of: 0 (iv) Shared power to dispose or direct the disposition of: 2,873 Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following . Item 6. This Item 6 is not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. This Item 7 is not applicable. Item 8. Identification and Classification of Members of the Group. This Item 8 is not applicable. Item 9. Notice of Dissolution of Group. This Item 9 is not applicable. Item 10 . Certification. (if filing pursuant to Rule 13d-1(c)) By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 21833P301 Page 7 of 9 Pages SIGNATURE After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: November 14, 2024 K2 HEALTHVENTURES EQUITY TRUST LLC By: /s/ Anup Arora Name: Anup Arora Title: Managing Member PARAG SHAH By: /s/ Parag Shah ANUP ARORA By: /s/ Anup Arora CUSIP No. 21833P301 Page 8 of 9 Pages

View Full Filing

View this SC 13G/A filing on SEC EDGAR